Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus

The glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have become important options for the management of patients with type 2 diabetes mellitus. While the GLP-1R agonists and DPP-4 inhibitors act on the incretin system to regulate glucose homeostasis,...

Descripción completa

Detalles Bibliográficos
Autor principal: Cobble, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310739/
https://www.ncbi.nlm.nih.gov/pubmed/22390369
http://dx.doi.org/10.1186/1758-5996-4-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310739/
https://www.ncbi.nlm.nih.gov/pubmed/22390369
http://dx.doi.org/10.1186/1758-5996-4-8

Ejemplares similares